◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Ascendis Pharma AS (ASND)

Name: Ascendis Pharma AS（ASND）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

HEALTHCARE · 华尔街（美国） · 最近更新： 2026-11-04

Ascendis Pharma A/S 是一家生物制药公司，专注于开发基于 TransCon 的疗法，以满足欧洲、美国和国际上未满足的医疗需求。该公司提供 SKYTROFA 用于治疗生长激素缺乏症的儿科患者； YORVIPATH，一种每日一次的皮下注射剂，用于治疗成人慢性甲状旁腺功能减退症。它还正在开发一系列处于临床开发阶段的独立内分泌罕见疾病候选产品，并专注于推进肿瘤治疗候选产品。该公司成立于 2006 年，总部位于丹麦海勒鲁普。

机器翻译

关键数据

市值: $16 billion
收入（截至 2025-12-31 财年）: €692M
净利润: (€219M)
毛利率: 85.1%
净利率: -31.7%

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
总收入	€1.0B	€692M	€364M	€267M	€51M	€8M	€7M	€13M	€11M	€2M	€5M	€8M	€14M	€20M	€16M
毛利	€950M	€589M	€319M	€222M	€39M	€4M	€7M	€13M	€11M	€2M	€5M	€8M	€14M	€20M	€16M
毛利率%	90.6%	85.1%	87.8%	83.4%	76.3%	54.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
营业利润（EBIT）	€266M	(€131M)	(€279M)	(€456M)	(€562M)	(€452M)	(€331M)	(€227M)	(€155M)	(€112M)	(€73M)	(€42M)	(€12M)	€5M	€2M
营业利润率%	25.4%	-18.9%	-76.7%	-170.8%	-1097.9%	-5808.6%	-4755.1%	-1695.1%	-1462.6%	-7290.3%	-1583.2%	-515.2%	-85.7%	25.9%	9.7%
净利	€753M	(€219M)	(€378M)	(€481M)	(€583M)	(€384M)	(€419M)	(€218M)	(€130M)	(€124M)	(€69M)	(€33M)	(€10M)	€4M	€1M
净利润率 %	71.8%	-31.7%	-104.0%	-180.5%	-1139.6%	-4931.6%	-6025.5%	-1630.0%	-1229.5%	-8097.8%	-1487.3%	-405.5%	-69.1%	20.0%	8.0%
EBITDA	—	(€110M)	(€290M)	(€411M)	(€529M)	(€365M)	(€408M)	(€210M)	(€150M)	(€110M)	(€72M)	(€33M)	(€11M)	€6M	€2M
每股收益（EPS）	€11.20	€-3.61	€-6.53	€-8.55	€-10.40	€-7.00	€-8.28	€-4.69	€-3.17	€-3.68	€-2.58	€-1.39	€-0.57	€0.38	€0.12
已发行股数 (M)	—	61M	58M	56M	56M	55M	51M	47M	41M	34M	27M	24M	17M	11M	11M

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 ASND 交互式查看器。 /companies/us/ASND

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.